Cargando…

French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge

In this special issue, we present the main highlights of the first weeks of pharmacovigilance monitoring of coronavirus disease 2019 (COVID-19) vaccines in this unprecedented situation in France: the deployment of a vaccination during an epidemic period with the aim of vaccinating the entire populat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lacroix, Clémence, Salvo, Francesco, Gras-Champel, Valérie, Gautier, Sophie, Massy, Nathalie, Valnet-Rabier, Marie-Blanche, Grandvuillemin, Aurélie, Mounier, Céline, Benkebil, Mehdi, Pariente, Antoine, Jonville-Béra, Annie-Pierre, Micallef, Joëlle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2021
Materias:	COVID-19/Pharmacovigilance
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103768/ https://www.ncbi.nlm.nih.gov/pubmed/34059351 http://dx.doi.org/10.1016/j.therap.2021.05.003

Ejemplares similares

Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: A win-win bet with Health Authorities!
por: Jonville-Bera, Annie Pierre, et al.
Publicado: (2023)

Pharmacovigilance signals from active surveillance of mRNA platform vaccines (tozinameran and elasomeran)
por: Valnet-Rabier, Marie-Blanche, et al.
Publicado: (2023)

Pharmacovigilance des médicaments et des vaccins contre la COVID-19 durant la pandémie : comment le Réseau français des centres régionaux de pharmacovigilance a relevé le défi ?
por: Jonville-Bera, Annie Pierre, et al.
Publicado: (2023)

Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic
por: Grandvuillemin, Aurélie, et al.
Publicado: (2023)

Role of spontaneous reporting in investigating the relationship between mRNA COVID-19 vaccines and myocarditis: The French perspective
por: Salvo, Francesco, et al.
Publicado: (2023)

Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres
por: Gras-Champel, Valérie, et al.
Publicado: (2021)

French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023)

COVID-19 vaccines surveillance in France: a global response to a major national challenge
por: Benkebil, Mehdi, et al.
Publicado: (2021)

COVID-19 et vaccins à adénovirus : expérience française de suivi renforcé de pharmacovigilance
por: Massy, Nathalie, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic
por: Lory, Pauline, et al.
Publicado: (2022)

Peripheral facial palsy post SARS-CoV-2 vaccine: A regional pharmacovigilance cases series
por: Chamboux, Morgane, et al.
Publicado: (2023)

French Pharmacovigilance Public System and COVID-19 Pandemic
por: Grandvuillemin, Aurélie, et al.
Publicado: (2020)

Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic
por: Lory, Pauline, et al.
Publicado: (2022)

A day in the life of a pharmacovigilance case processor
por: Bhangale, Ritesh, et al.
Publicado: (2017)

Global research output in ‘pharmacovigilance’ during 2010–2020
por: Tyagi, Sunil
Publicado: (2022)

Pharmacovigilance for clinical trials in India: Current practice and areas for reform
por: Brahmachari, Ballari, et al.
Publicado: (2011)

Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre
por: Istampoulouoglou, Ioanna, et al.
Publicado: (2021)

Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre
por: Istampoulouoglou, Ioanna, et al.
Publicado: (2021)

Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy
por: Soeiro, Thomas, et al.
Publicado: (2021)

Pharmacovigilance and assessment of drug safety reports during COVID 19
por: Desai, Mira K
Publicado: (2020)

Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India
por: Thota, Prasad, et al.
Publicado: (2018)

Causality assessment: A brief insight into practices in pharmaceutical industry
por: Naidu, R. Purushotham
Publicado: (2013)

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
por: Mendell, Jeanne, et al.
Publicado: (2015)

Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports
por: Salem, M., et al.
Publicado: (2017)

Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data
por: Steffen, Annika, et al.
Publicado: (2018)

Understanding the molecular–pharmaceutical basis of sartan recalls focusing on valsartan
por: Ray, Avik, et al.
Publicado: (2020)

A case of intoxication with tea made from Digitalis purpurea
por: Lehmann, Anouk, et al.
Publicado: (2021)

Colchicine and macrolides: a cohort study of the risk of adverse outcomes associated with concomitant exposure
por: Tan, Malinda S., et al.
Publicado: (2022)

Vaccines and Bell's palsy: A narrative review
por: Bertin, Blandine, et al.
Publicado: (2023)

The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans
por: Dal-Ré, Rafael
Publicado: (2023)

Pharmacovigilance in China: Evolution and future challenges
por: Song, Haibo, et al.
Publicado: (2022)

Patient involvement in pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France
por: Adopo, D., et al.
Publicado: (2022)

Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data
por: Martin, Guillaume L., et al.
Publicado: (2022)

De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring
por: Moulis, Guillaume, et al.
Publicado: (2022)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database
por: Létinier, Louis, et al.
Publicado: (2021)

Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions
por: Létinier, Louis, et al.
Publicado: (2021)

Enhancing self-medication practices in the era of infodemic: the role of pharmacovigilance
por: Calderon-Ospina, Carlos-Alberto
Publicado: (2023)

Small intestinal injury in NSAID users suffering from rheumatoid arthritis or osteoarthritis
por: Tachecí, Ilja, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2mb9e351bcqpn3m0r5ajsloscl